Inventia Life

What Inventia Life does

Inventia Life Science is an Australian biotechnology company headquartered in Sydney that develops the RASTRUM 3D cell culture platform for drug discovery, cancer research, and personalized medicine applications. The platform is built around a proprietary inkjet-based cell deposition method that produces reproducible, assay-ready 3D cell models in standard multi-well plate formats. The product portfolio comprises the core RASTRUM system, the high-throughput RASTRUM Allegro, RASTRUM Cloud for workflow and data management, configurable cell model architectures, standardized matrices, and predefined workflow paths (Discovery Mode for exploratory biology and Validated Solutions for defined contexts of use). The company also markets LIGŌ as a separate sub-brand and offers Discovery Services for expert scientific support.

The company sells primarily to pharmaceutical and biotechnology enterprises running drug discovery, target identification, lead validation, mechanism-of-action studies, and toxicology workflows, with cancer research organizations as a secondary segment. Revenue is generated through three streams: capital and consumable sales tied to the RASTRUM instrument installed base, recurring access to RASTRUM Cloud, and fee-based Discovery Services engagements. Pricing is quote-based and not publicly disclosed, with buying routed through specialist consultation. Go-to-market combines enterprise field sales, a specialist-led inside-sales/discovery services motion, and content marketing across website, social, email, and conferences. The company is headquartered in Sydney with a newly launched US sales operation covering the US and Canada, supported by a Series B of AU$35 million (~$25 million USD) in December 2021 led by Blackbird Ventures and a subsequent 2023 round from Tenmile.

Name

Inventia Life

Legal name

Inventia Life Science

Website

https://inventia.life

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

3D Cell Culture Instruments and Bioprinting Platforms

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

akta.pro secondary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• 3D cell culture
• Bioprinting technology
• Drug discovery platforms
• Cancer research tools
• Phenotypic screening

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. 3D Cell Culture Platform Sales: Sale of RASTRUM platform systems and consumables for 3D cell culture, including the RASTRUM Allegro high-throughput system and associated reagents and matrices.
2. Discovery Services: Expert support services to accelerate drug discovery programs, from model optimization to screening workflows. Professional services engagement model.
3. RASTRUM Cloud Platform: Cloud-based software platform for managing 3D cell culture workflows and data, likely subscription-based access.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Inventia Life Science develops and sells the RASTRUM 3D bioprinting platform, an inkjet-based system that generates reproducible, assay-ready 3D cell models in standard multi-well plates for drug discovery, cancer research, and personalized medicine applications. The platform is complemented by proprietary matrix consumables, RASTRUM Cloud software, standardized workflow paths, and expert Discovery Services to support pharmaceutical and biotechnology research teams.

Product overview

Inventia Life Science offers a unified platform-plus-modules architecture centered on the RASTRUM™ system for scalable 3D cell culture. The core RASTRUM™ platform and its high-throughput variant RASTRUM™ Allegro work in conjunction with RASTRUM™ Cloud, RASTRUM Workflow Paths (Discovery Mode and Validated Solutions), Cell Model Architectures, and Matrices to enable reproducible, decision-grade 3D cell modeling. The portfolio is complemented by Discovery Services for expert scientific support. Applications span cancer research, drug discovery, and personalized medicine. The company also offers LIGŌ as a sub-brand.

Differentiator

Problem solved

Functional benefit

Brands

• RASTRUM™: Advanced 3D cell culture platform enabling assay-ready 3D models in standard plates for drug discovery, cancer research, and disease modeling with reproducible and scalable results.
• RASTRUM™ Allegro
• RASTRUM™ Cloud
• LIGŌ

Products and services

• RASTRUM

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• BICO (CELLINK): BICO, via the CELLINK brand, is the leading dedicated 3D bioprinting and lab automation platform for life sciences. Directly comparable to Inventia as both sell bioprinters, bioinks, and consumables into pharma/biotech research customers.
• Organovo: Pioneer in 3D bioprinted human tissues for drug discovery and disease modeling. Comparable to Inventia in targeting pharma/biotech customers with 3D tissue models, though Organovo has historically focused on therapeutic tissue applications.
• Aspect Biosystems: Develops microfluidic 3D bioprinting technology for drug discovery and regenerative medicine. Comparable to Inventia in the bioprinting platform business, though Aspect emphasizes tissue therapeutics while Inventia emphasizes drug discovery workflows.
• MIMETAS: Offers organ-on-chip and 3D cell culture platforms for preclinical drug discovery. Comparable to Inventia in selling human-relevant 3D biology tools to pharma/biotech for target validation, toxicology, and disease modeling.
• Emulate: Provides organ-on-chip platforms used in pharma R&D for predictive modeling of human biology. Comparable to Inventia as a higher-fidelity alternative to 2D cell culture serving the same pharma/biotech buyer base.
• InSphero: Specializes in 3D microtissue and organoid technology for drug discovery and safety testing. Comparable to Inventia in delivering standardized, reproducible 3D cell models to pharma/biotech customers.

Emerging players

• CN Bio: Develops organ-on-chip and microphysiological systems for drug development. Comparable to Inventia as a niche player offering higher-fidelity in vitro human biology to pharma, though with a narrower product portfolio.

Broad incumbents

• Corning Life Sciences: Major supplier of cell culture vessels, media, and 3D culture products (including Matrigel-equivalent matrices). Comparable to Inventia as a broad incumbent competing on the cell-culture consumables side of the workflow.
• Sartorius: Global bioprocessing and lab products supplier serving biopharma R&D and manufacturing. Comparable to Inventia as a broad incumbent selling into the same pharma/biotech buyer with a much wider catalog.
• Thermo Fisher Scientific: Largest life sciences tools and services company, with deep coverage of cell culture, instruments, and lab consumables. Comparable to Inventia as the dominant incumbent against which smaller 3D culture vendors must compete for shelf space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCBAr_UySphuEBWEmElHMqUw
• Facebookfacebook.com/inventia.life.science
• LinkedInlinkedin.com/company/inventia-life-science
• Xx.com/InventiaLifeSci

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inventia Life